Interpretation of the new definition of extensive drug-resistant tuberculosis defined by World Health Organization

doi:10.3969/j.issn.1000-6621.2021.06.003

Abstract

Abstract:

The definition of extensive drug-resistant tuberculosis (XDR-TB) first proposed by World Health Organization (WHO) in 2006 has played an important role in guiding the prevention and control of drug-resistant tuberculosis. With the development of new diagnostic technologies and new drugs, WHO updated the original definition of XDR-TB in January 2021. In this paper, the background, history, reasons and general principles of the new definition of XDR-TB were interpreted, and the impact and significance of the new definition for the tuberculosis control in the future were summarized, in order to provide reference for tuberculosis control workers in China.

Key words: Extensively drug-resistant tuberculosis, Concept formation, Benchmarking

LI Ren-zhong, RUAN Yun-zhou, LI Yu-hong. Interpretation of the new definition of extensive drug-resistant tuberculosis defined by World Health Organization[J]. Chinese Journal of Antituberculosis, 2021, 43(6): 539-541. doi: 10.3969/j.issn.1000-6621.2021.06.003

References 11

[1]	World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27-29 October 2020. Geneva: World Health Organization, 2021.
[2]	O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. London: Government of the United Kingdom, 2016.
[3]	Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis, 2007,13(3):380-387. doi: 10.3201/eid1303.061400. doi: 10.3201/eid1303.061400 URL
[4]	World Health Organization. Guidelines for the management of drug-resistant tuberculosis. Geneva: World Health Organization, 1997.
[5]	World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2006.
[6]	World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva: World Health Organization, 2016.
[7]	World Health Organization. WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update. Geneva: World Health Organization, 2018.
[8]	World Health Organization. WHO consolidated guidelines on tuberculosis, Module 4: treatment-drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2020.
[9]	World Health Organization. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs: policy guidance. Geneva: World Health Organization, 2016.
[10]	World Health Organization. WHO consolidated guidelines on tuberculosis. module 3: diagnosis: rapid diagnostics for tuberculosis detection. Geneva: World Health Organization, 2020.
[11]	中华人民共和国国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发中国结核病预防控制工作技术规范(2020年版)的通知. 国卫办疾控函〔2020〕279号. 2020-04-02.

[1]	Duan Hongfei, Tao Yong. Interpretation of social organization standard of Diagnosis Specification of Intraocular Tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 258-261.
[2]	WU Guo-lan, GAO Jing-tao, CHEN Xiao-hong, CHEN Li-zhou, WENG Li-zhen, GUO Zhi-ping, CHEN Xiu-ping, LIN Jian-dong, CHEN Su-xia, GAO Meng-qiu, LIU Yu-hong. Short-term effectiveness and safety of a regimen containing bedaquiline in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 899-904.
[3]	SHI Zheng-yu, WU Gui-hui, HUANG Tao, LIU Yu-hong, GAO Meng-qiu, CHEN Lei, LI Xi, YANG Ming, HE Wei, CHEN Yan, LU Xiao-li, GAO Jing-tao, LI Liang. Early effectiveness and safety of bedaquiline containing regimen in treatment of multidrug-resistant and extensively drug-resistant tuberculosis: An one arm observational study of 24 weeks [J]. Chinese Journal of Antituberculosis, 2021, 43(5): 487-494.
[4]	PEI Yi, GAO Jing-tao, HUANG Yun-hui, HE Fang, FENG Wen-jun, YANG Xiao-yun, HU Yu-meng, LEI Li-ping, SHI Li. Analysis of efficacy in the treatment of 44 pulmonary tuberculosis patients with mycobacterium culture-positive multidrug-resistant/extensively drug-resistant with bedaquiline-containing regimen for 24 weeks [J]. Chinese Journal of Antituberculosis, 2021, 43(11): 1139-1145.
[5]	YANG Chun-long, ZHOU Lin, CHEN Ming-ting. Interpretation of the Diagnosis process for etiology negative pulmonary tuberculosis (T/CHATA 008—2020) [J]. Chinese Journal of Antituberculosis, 2021, 43(11): 1116-1119.
[6]	TIAN Dan, HU Xiao-meng, JIN Wu, CHENG Chang-hao, XIONG Lei-qun, HU Rong-hua, JIN Qian, LIU Yun, DU Juan. Sixty-seven MDR-,and XDR-PTB cases with sputum culture conversion then treated with bedaquiline-containing regimens: A singal arm, single center observational study [J]. Chinese Journal of Antituberculosis, 2021, 43(11): 1146-1152.
[7]	SHEN Xin, XIAO Xiao, BAI Li-qiong, PAN Qi-chao. Interpretation of the Guidelines on management of close contacts of active pulmonary tuberculosis cases in schools [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 990-991.
[8]	CHENG Jun. Interpretation of the Specification of tuberculosis examination for student entrance physical examination [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 987-989.
[9]	ZHANG Can-you, XIA Hui, CHENG Jun. Testing and reporting requirements for Class Ⅱ biosafety cabinet in tuberculosis laboratory [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 903-909.
[10]	The Group of Osteoarticular Tuberculosis. Guidelines on surgical treatment of osteoarticular tuberculosis in facing novel coronavirus pneumonia [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 185-190.
[11]	SUN Ming-lei, GUAN Li, ZHAO Juan, WANG Chen, ZOU Dan-dan, LIANG Li-bo. Legislative considerations on traffic travel of MDR-TB/XDR-TB patients from the perspective of infectious disease prevention and control [J]. Chinese Journal of Antituberculosis, 2020, 42(12): 1268-1271.
[12]	YING Ruo-yan, HUANG Xiao-chen, WANG Jie, LIU Yi-dian, SHA Wei, YANG Hua. Clinical analysis of drug sensitivity tests of various drug-resistant MTB isolates against different combinations of anti-tuberculosis drugs in vitro [J]. Chinese Journal of Antituberculosis, 2020, 42(11): 1183-1182.
[13]	XU Cai-hong, ZHANG Hui, LIU Jian-jun. Interpretation of the Employees Health Examination Specification-Tuberculosis Examination [J]. Chinese Journal of Antituberculosis, 2020, 42(10): 1134-1136.
[14]	Shi-wen JIANG,Xiao-qiu LIU. Interpretation of key points and suggestion for the Health Management Service Specification for Tuberculosis Patients [J]. Chinese Journal of Antituberculosis, 2019, 41(9): 926-929.
[15]	FAN Lin,XIONG Kun-long,XIAO He-ping. Historic review of anti-tuberculosis chemotherapy during seventy years of the People’s Republic of China [J]. Chinese Journal of Antituberculosis, 2019, 41(11): 1145-1148.